Breast Cancer Research and Treatment

, Volume 126, Issue 2, pp 471–478 | Cite as

The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients

  • Soo Youn Bae
  • Se Kyung Lee
  • Min Young Koo
  • Sung Mo Hur
  • Min-Young Choi
  • Dong Hui Cho
  • Sangmin Kim
  • Jun-Ho Choe
  • Jeong Eon Lee
  • Jung-Han Kim
  • Jee Soo Kim
  • Seok Jin Nam
  • Jung-Hyun Yang
Clinical trial

Abstract

Metaplastic breast carcinoma (MBC) is a rare, heterogeneous breast cancer characterized by admixture of adenocarcinoma with metaplastic elements, low hormone receptor expression, and poor outcomes. The authors retrospectively reviewed the medical records of 47 MBC patients and 1,346 invasive ductal carcinoma (IDC) patients. Two hundred eighteen of the IDC patients were triple-negative (TN-IDC) for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (ER-/PR-/HER2-). Patients were surgically treated at the Samsung Medical Center between 2005 and 2009. The MBC patients presented with a larger tumor size, lower lymph node involvement, higher histological and nuclear grades, higher triple negativity (ER-/PR-/HER2-) and higher p53, CK5/6, and EGFR expressions compared with those of the IDC group. However, there were no significant differences in clinicopathological characteristics between MBC and TN-IDC. During the follow-up period (median duration of 30.3 months, range 2.6–56.3 months), seven (14.9%) MBC patients, and 98 (7.1%) IDC patients had disease recurrence. The three-year disease-free survival (DFS) rate was 78.1% in the MBC group and 91.1% in IDC group (P < 0.001). The three-year DFS rate was not significantly different between the MBC and TN-IDC groups (78.1 vs. 84.9%, P = 0.114). However, in patients with lymph node metastasis who underwent adjuvant chemotherapy, the three-year DFS rate was 44.4% in the MBC group and 72.5% in the TN-IDC group (P = 0.025). The authors found that MBC had a poorer clinical outcome than did IDC. In breast cancer patients with nodal metastasis, MBC had a poorer prognosis than did TN-IDC, despite adjuvant chemotherapy.

Keywords

Metaplastic breast cancer Invasive ductal carcinoma Triple-negative breast cancer Prognosis Adjuvant chemotherapy 

Notes

Acknowledgment

This work was supported by a grant of the Korea Healthcare technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea (NTX2101012).

References

  1. 1.
    Oberman HA (1987) Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol 11:918–929PubMedCrossRefGoogle Scholar
  2. 2.
    Tavassoli FA (1992) Classification of metaplastic carcinomas of the breast. Pathol Annu 27(Pt 2):89–119PubMedGoogle Scholar
  3. 3.
    Huvos AG, Lucas JC Jr, Foote FW Jr (1973) Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med 73:1078–1082PubMedGoogle Scholar
  4. 4.
    Grechi G, Pagnini P (1965) Study of mammary gland neoplasms with an osteocartilaginous component. I. Cartilaginous metaplastic epiphenomena in the course of connective tissue malignancy. Arch De Vecchi Anat Patol 46:277–303PubMedGoogle Scholar
  5. 5.
    Tavassoli FA, Devilee P (2003) World health organization: Tumours of the breast and female genital organs. Oxford University, OxfordshireGoogle Scholar
  6. 6.
    Wargotz ES, Deos PH, Norris HJ (1989) Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol 20:732–740PubMedCrossRefGoogle Scholar
  7. 7.
    Wargotz ES, Norris HJ (1989) Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 64:1490–1499PubMedCrossRefGoogle Scholar
  8. 8.
    Wargotz ES, Norris HJ (1989) Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 20:628–635PubMedCrossRefGoogle Scholar
  9. 9.
    Wargotz ES, Norris HJ (1990) Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 21:1142–1150PubMedCrossRefGoogle Scholar
  10. 10.
    Wargotz ES, Norris HJ (1990) Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 65:272–276PubMedCrossRefGoogle Scholar
  11. 11.
    Beatty JD, Atwood M, Tickman R, Reiner M (2006) Metaplastic breast cancer: clinical significance. Am J Surg 191:657–664PubMedCrossRefGoogle Scholar
  12. 12.
    Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K (2007) Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 14:166–173PubMedCrossRefGoogle Scholar
  13. 13.
    Gutman H, Pollock RE, Janjan NA, Johnston DA (1995) Biologic distinctions and therapeutic implications of sarcomatoid metaplasia of epithelial carcinoma of the breast. J Am Coll Surg 180:193–199PubMedGoogle Scholar
  14. 14.
    Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. Cancer 63:181–187PubMedCrossRefGoogle Scholar
  15. 15.
    Lim KH, Oh DY, Chie EK, Han W, Im SA, Kim TY, Park IA, Noh DY, Ha SW, Bang YJ (2010) Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity. Jpn J Clin Oncol 40:112–118PubMedCrossRefGoogle Scholar
  16. 16.
    Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, Kwon Y, Kim EA, Ko KL, Shin KH, Lee KS, Park IH, Lee S, Kim SW, Kang HS, Ro J (2010) Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 120:627–637PubMedCrossRefGoogle Scholar
  17. 17.
    Barnes PJ, Boutilier R, Chiasson D, Rayson D (2005) Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat 91:173–178PubMedCrossRefGoogle Scholar
  18. 18.
    Khan HN, Wyld L, Dunne B, Lee AH, Pinder SE, Evans AJ, Robertson JF (2003) Spindle cell carcinoma of the breast: a case series of a rare histological subtype. Eur J Surg Oncol 29:600–603PubMedCrossRefGoogle Scholar
  19. 19.
    Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRefGoogle Scholar
  20. 20.
    Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482–1485PubMedGoogle Scholar
  21. 21.
    Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264–271PubMedCrossRefGoogle Scholar
  22. 22.
    Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Soo Youn Bae
    • 1
  • Se Kyung Lee
    • 1
  • Min Young Koo
    • 1
  • Sung Mo Hur
    • 1
  • Min-Young Choi
    • 1
  • Dong Hui Cho
    • 1
  • Sangmin Kim
    • 1
  • Jun-Ho Choe
    • 1
  • Jeong Eon Lee
    • 1
  • Jung-Han Kim
    • 1
  • Jee Soo Kim
    • 1
  • Seok Jin Nam
    • 1
  • Jung-Hyun Yang
    • 1
  1. 1.Department of Surgery, Division of Breast and Endocrine Surgery, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea

Personalised recommendations